At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 176 enrolled
Drug / intervention
dorzolamide hydrochloride (+) timolol maleatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s)
In Brief
A Phase 4 clinical trial evaluating dorzolamide hydrochloride (+) timolol maleate for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 176 participants.
Detailed Summary
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open Angle Glaucoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedOct 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedOct 17, 2007
Enrollment StartMay 23, 2007
Primary CompletionSep 15, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.7 years ago
Interventions
dorzolamide hydrochloride (+) timolol maleatedrug
dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment